Liquid Biopsy Market Growth, Trend, Price, Demand and Forecast Liquid Biopsy Market - Global Industry Analysis, S

Liquid Biopsy Market - Global Industry Analysis, Size, Share,
Growth, Trends, and Forecast 2017 – 2025
Liquid biopsy is a rapid plasma genotyping technique, which provides overview of karyotypic
abnormalities in the circulating tumor cells present in the blood sample. The solid-tissue biopsies are
used in cancer diagnostics; however, the liquid biopsy technique is rapidly gaining momentum due to
its minimal invasiveness. The liquid biopsy field is a result of years of research for identification of
cancer biomarkers, and many of its highly promising detection subjects, such as extracellular vesicles,
are yet to be fully developed for their commercial applications. These are point-of-care sequencing-
based techniques, and the important insights obtained from studies of liquid biopsy subjects have
quickened the development of cancer diagnostics.
Request for brochure of this report -
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=22994
The emerging trend in the liquid biopsy field is the development of in-depth analytical cancer diagnostic
studies for cancer prognosis and metastasis of some cancer types whose conventional tissue biopsies
are complicated to carry out. The global liquid biopsy market is driven by superior technological
innovations of new tests designed for cancer state monitoring, with increased sensitivities for
circulating tumor cells, along with its minimum invasiveness, superiority in genetic anomaly detection
than solid tumor biopsies, and increasing awareness through social initiatives. However, issues with
reimbursement policies and changing governmental policies are expected to restrain the market.
The liquid biopsy market has been segmented based on biomarker type, cancer type, test type,
application, and end-user. In terms of biomarker type, the market has been classified into circulating
tumor DNA (ctDNA), circulating tumor cell (CTC), extracellular vesicle (EV), and other biomarkers.
Liquid biopsy was first developed using circulating tumor cells, and since then most of the tests have
been developed using these biomarkers. Currently, the number of clinical trials for ctDNA analysis are
increasing because the concentration of ctDNA in the blood stream is higher as compared to CTC.
This is expected to reflect in the changing dynamics of the market during the forecast period. Based
on cancer type, the market has been divided into lung cancer, blood cancer, breast cancer, liver
cancer, prostate cancer, and others. In terms of test type, the global liquid biopsy market is bifurcated
into single gene assays and multi-gene assays. Based on application, the market has been
categorized into diagnosis analysis, prognosis analysis, cancer monitoring, and recurrence analysis.
In terms of end-user, the market has been segmented into hospital laboratories, diagnostic
laboratories, academic and research institutes, and others.
In terms of region, the global liquid biopsy market is divided into five regions: North America, Europe,
Asia Pacific, Latin America, and Middle East & Africa. The market in Asia Pacific is expected to register
a high CAGR owing to factors such as increasing physician inclination toward advanced and minimally
invasive techniques for cancer diagnosis, rising prevalence of different cancer types, and growth in
per capital health expenditure of the overall population in this region. North America is anticipated to
dominate the global liquid biopsy market due to high adoption of technologically advanced products